Old Web
English
Sign In
Acemap
>
authorDetail
>
Masyar Gardizi
Masyar Gardizi
Angiogenesis
Medicine
Refractory
Maximum tolerated dose
Combination therapy
3
Papers
20
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
BARIS: A phase I trial to evaluate the safety and tolerability of combined BIBF 1120 and RAD001 in solid tumors and to determine the maximum tolerated dose (MTD) of the combination.
2014
Journal of Clinical Oncology
Matthias Scheffler
Lucia Nogová
Masyar Gardizi
Marc Bos
Irini Papachristou
Martin L. Sos
Thomas Zander
Christian Mattonet
Juergen Wolf
Show All
Source
Cite
Save
Citations (2)
Angiopoietin-1 und Angiopoietin-2 als Serummarker für das Maligne Melanom
2013
Masyar Gardizi
Show All
Source
Cite
Save
Citations (0)
A decreased ratio between serum levels of the antagonistic angiopoietins 1 and 2 indicates tumour progression of malignant melanoma.
2012
Archives of Dermatological Research
Masyar Gardizi
Christine Kurschat
Anna Riese
Moritz Hahn
Thomas Krieg
Cornelia Mauch
Peter Kurschat
Show All
Source
Cite
Save
Citations (18)
1